UFLEX Q1 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹3,901 Cr
verified against source
Revenue YoY
6.5%
reported change
EBITDA
Pending
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
UFLEX reported a mixed Q1 FY26 with revenue growth of 6.5% YoY driven by 7.9% volume increase, though EBITDA margin contracted 70bps to 12% vs 12.7% last year due to pre-tariff customer destocking and cost pressures. Packaging films volume grew 6.8% while liquid packaging surged 18% YoY. India capacity utilization reached 97% and Egypt 75%. A competitor's plant accident in late May improved supply-demand dynamics, supporting better pricing—full margin impact expected in Q2-Q4. US tariff uncertainty remains a headwind, though Mexico exports benefit from USMCA nil duty. Management maintained FY26 guidance of Rs 3,000 crore incremental revenue and Rs 600 crore EBITDA from new capex (Rs 2,000 crore total, Rs 1,100 crore spent). Aseptic packaging volume guidance trimmed to 8.5-9 billion packs from 10 billion due to commissioning delay to H2 FY26. Risk includes rising imports from China/Southeast Asia checking BOPET margin recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Expected to add Rs 3,000 crore of incremental revenue at 85% capacity utilization levels with Rs 600 crore EBITDA contribution
- Revised guidance of 8.5-9 billion packs for FY26 (down from 10 billion) due to commissioning delay now expected in H2 FY26
- Net debt to EBITDA expected to decline below 3x as new projects commission and profitability kicks in from FY27 onwards
- Q2-Q4 EBITDA margins expected to improve driven by supply-side tightening post competitor accident and stabilized tariff environment
Risks flagged
- Additional 25% secondary tariff on Indian exports to US creates uncertainty; management expects resolution or extension beyond July 27 deadline but impact on Q2 order flow remains unclear
- Greenfield expansion delayed beyond January 2025 calendar season start; full benefit now expected only from CY26 onwards, reducing FY26 revenue upside
- Analyst raised concern about higher imports checking BOPET margin recovery in India; management acknowledged imports compressed margins post-competitor accident benefit
- Nigeria sequential decline attributed to US tariff impact; customers pre-stocked inventory before 19% duty announcement; recovery timeline unclear
Key quotes
- The exports from India to Europe have come down and the local availability of BOPET and BOP films has also gone down with the result that the demand supply is more balanced now which has led to better margins post this event
- If the tariffs are between 15 to 20% range final tariffs, I think we'll be at a level playing field with other countries supplying to US and that will put us almost at par in terms of pricing competitiveness
- The margin for this quarter has been slightly lower. Same period last year we had a 12.7% EBITDA margin but this quarter it is 12%. The India business has done well but because of the tariff uncertainties and companies stocking material in advance, we've seen some impact
Research modules